DB
VRCA icon

Dmitry Balyasny’s Verrica Pharmaceuticals VRCA Stock Holding History

Dmitry Balyasny’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,531
Closed -$478K – 3159
2023
Q4 		$478K Buy
+6,531
New +$268K ﹤0.01% 1970

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Dmitry Balyasny's VRCA Position: Q1 2024 in Review

Dmitry Balyasny sold out of Verrica Pharmaceuticals (VRCA) in Q1 2024, closing a stake of 6,531 shares — an estimated $478K sold.

Dmitry Balyasny first reported a position in VRCA in Q4 2023 and held it in 1 quarter. The position peaked at $478K in Q4 2023. 60 funds tracked by Wall St. Rank hold VRCA as of Q1 2024.

  • Dmitry Balyasny reported no remaining Verrica Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 6,531 Verrica Pharmaceuticals shares in Q1 2024, an estimated $478K.
  • Dmitry Balyasny first reported a position in Verrica Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Dmitry Balyasny's Verrica Pharmaceuticals position peaked at $478K in Q4 2023.
  • 60 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.